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Introduction {#sec005}
============

LC is the most common malignant tumor and the leading cause of cancer death for both sexes worldwide \[[@pone.0182117.ref001],[@pone.0182117.ref002]\]. In 2015, the American Cancer Society estimated that LC was responsible for 158,040 deaths, accounting for approximately 26.8% of all deaths from cancer \[[@pone.0182117.ref003]\]. The average 5-year survival of LC patients is only 17%; in most patients, LC is usually advanced at the time of diagnosis, with 5-year survival rates as low as only 4% \[[@pone.0182117.ref003]\]. Therefore, early detection and immediate initiation of treatment are regarded as the mainstay to reduce the mortality of LC and improve the 5-year survival rate to 70--80% \[[@pone.0182117.ref004], [@pone.0182117.ref005]\]. However, because only 16% of LC patients are diagnosed at stage I \[[@pone.0182117.ref006]\], the detection of early stage LC patients represents a critical and challenging need in the management of this deadly disease. At present, few early detection tests or acceptable screening methods for this disease are available. Although low-dose spiral computed tomography (LDCT) has been shown to be highly sensitive for the early detection of small lung nodules and has led to a 20% reduction in LC mortality \[[@pone.0182117.ref007]\]. However, LDCT presents several limitations, including a high false-positive rate (as high as 50% in prevalence), repeated radiation exposure and substantial costs, which limit its widespread application as a screening procedure \[[@pone.0182117.ref008]--[@pone.0182117.ref010]\]. Therefore, it is necessary to develop more effective, non-invasive methods for the screening and early diagnosis of LC.

Current research efforts aim to identify the best potential and cost-effective blood biomarkers for the early detection of LC. A valid biomarker could provide additional evidence as to whether a suspicious, screening-detected nodule was malignant or not, thereby reducing the number of false positives at surgery or surgical biopsy \[[@pone.0182117.ref011]\]. Present diagnostic blood tests focus on detecting tumor-associated antigen (TAA) markers such as carcinoembryonic antigen (CEA), chromogranin, neuron-specific enolase, carbohydrate antigen (CA) 125, and CA19-9, which show an increased positivity at advanced stages \[[@pone.0182117.ref012]\] but are rarely used as early biomarkers because of their low sensitivity and specificity. However, blood tests of serum tumor-associated autoantibodies (TAAbs) against overexpressed, mutated, misfolded, or aberrant autologous cellular antigens produced by cancer cells \[[@pone.0182117.ref011],[@pone.0182117.ref013]\], may identify individuals with early lung cancer and distinguish high risk smokers with benign nodules from those with lung cancer. Autoantibodies to TAAs may persist in the circulating blood longer than the antigens themselves, and may be more easily detected and have the potential to be highly useful diagnostic markers in a variety of cancers, including LC. In the blood of patients who develop lung cancer, the circulating autoantibodies have been found up to 5 years before CT was able to identify the tumor \[[@pone.0182117.ref014]\].

Over the years, evidence has demonstrated the potential diagnostic values of autoantibodies and their application as biomarkers for LC. Moreover, a panel of assays for autoantibodies with various TAA specificities can effectively detect LC because of the heterogeneity of single antigen expression \[[@pone.0182117.ref015]\]. Two recent reviews \[[@pone.0182117.ref011],[@pone.0182117.ref016]\] have reported that panels of autoantibodies could be used as blood biomarkers to diagnose early LC or distinguish benign from malignant nodules; however, no meta-analysis was performed to evaluate the diagnostic accuracy of multiplex autoantibodies in these analyses. Furthermore, many relevant studies in this field have been recently published. Hence, we conducted a comprehensive review and meta-analysis to assess the diagnostic values of serum single and multiplex autoantibodies in the patients with lung cancer, especially for the early detection of LC.

Methods {#sec006}
=======

Search strategy {#sec007}
---------------

We searched relevant studies from the MEDLINE and EMBASE databases until September 26, 2016. The following combination of search terms was used to retrieve articles: (lung neoplasms OR lung carcinoma OR lung cancer OR lung tumor) AND (autoantibodies OR antibodies OR immunoglobulin) AND (sensitivity OR specificity OR accuracy) in the Title/Abstract. Related or additional articles were also identified by manually searching the references cited in the articles. This process was performed repeatedly until no additional articles could be identified. Although no language restrictions were imposed initially, the full-text review and final analysis were limited to articles published in English or Chinese. If evidence showed that some publications were associated with the same study (e.g., two or more articles with the same authors, institutions, or period of study), we only selected the most recent article and the best-quality study. Two authors (ZMT and ZGL) independently determined the study eligibility while screening the citations. Disagreements were resolved by discussion and consensus.

Study selection {#sec008}
---------------

We initially read the titles and abstract and obtained the full texts of the selected studies that met the eligibility criteria. To be included in our systematic review and meta-analysis, studies had to satisfy the following criteria: 1) the participants were evaluated for the presence of serum autoantibodies or antibodies; 2) the studies provided both the sensitivity and specificity of the levels of mixed autoantibodies for the diagnosis of lung cancer; and 3) studies included cancer-free patients or normal populations as a control group. Studies were excluded if they were: 1) conference abstracts and letters to journal editors; 2) reviews, meta-analyses, or proceedings; 3) studies concerning the function of autoantibodies in animal models; and 4) studies with small sample sizes (n\<10) to avoid selection bias.

Data extraction and quality assessment {#sec009}
--------------------------------------

Two reviewers (CMW and JLK) independently extracted the following information from all eligible articles: first author, year of publication, location, TAAs corresponding to autoantibodies, number of patients (including early-stage patients), test method, cut-off value or area under the curve (AUC), and evaluation indexes (sensitivity, specificity and accuracy). We computed manually the accuracy using the equation (diagnostic accuracy = 100×(number of true-positive + number of true negative)/total number of instances). We also computed the sensitivity and/or specificity for studies that did not report these estimates but provided sufficient information for their derivation. The extracted data were confirmed by another author (YBW).

Two independent researchers assessed the quality of the methodology of the included studies according to a new 11-item quality appraisal tool for studies of diagnostic reliability (QAREL, maximum score 11) \[[@pone.0182117.ref017]\], each item being assessed as "yes" or "no" or "unclear", and certain items being rated as 'not applicable'. When differences in scoring existed, a consensus was reached.

Statistical analysis {#sec010}
--------------------

The most frequently studied panel of TAAbs was selected as the subject of meta-analysis, which was performed using the Stata/SE 12.0 software (Stata Corp, College Station, Texas, USA). The pooled sensitivity and specificity forest plots were used to evaluate the diagnostic value of the same panel of autoantibodies, and the threshold effect was assessed using a summary receiver operating characteristic curve (SROC). The heterogeneity of the included studies was evaluated using an I^2^ statistic, which is a quantitative measure of inconsistencies across studies. Studies with an I^2^ statistic between 25 and 50% were considered to have low heterogeneity, whereas studies with an I^2^ statistic between 50 and 75% were considered to have moderate heterogeneity, and those with an I^2^ statistic \>75% were considered to have high heterogeneity \[[@pone.0182117.ref018]\]. If homogeneity was present, fixed- and random-effect models provided similar results; when substantial heterogeneity of the individuals (I^2^ \> 50%) was observed, a random-effect model only was used \[[@pone.0182117.ref019]\]. If heterogeneity was present, we performed a sensitivity analysis by omitting one study at a time to further explore the heterogeneity. If more than 10 studies were included in the meta-analysis, a funnel plot and Egger test were used to assess the publication bias.

Results {#sec011}
=======

Study identification and selection {#sec012}
----------------------------------

A total of 1,762 potentially relevant publications were identified by the initial independent search, and 305 articles were excluded because of duplication. Overall, 1,380 publications that did not meet the inclusion criteria were excluded based on the titles and abstracts. Among the remaining 77 full-text articles, 7 were excluded because no outcomes of interest were reported \[[@pone.0182117.ref020]--[@pone.0182117.ref026]\], 3 were excluded because the participants were not evaluated for serum autoantibodies \[[@pone.0182117.ref027]--[@pone.0182117.ref029]\], 2 were excluded because it was neither in English or Chinese \[[@pone.0182117.ref030],[@pone.0182117.ref031]\]. One article was excluded because the autoantibody was not performed in the serum \[[@pone.0182117.ref032]\], and another one was excluded because of duplicate data \[[@pone.0182117.ref033]\]. Two additional articles were identified by manual search \[[@pone.0182117.ref034],[@pone.0182117.ref035]\]. Finally, 65 articles were included in the present system review and meta-analysis \[[@pone.0182117.ref013],[@pone.0182117.ref014],[@pone.0182117.ref034]--[@pone.0182117.ref096]\], including 31 articles with single autoantibody and 39 with multiplex autoantibodies (5 articles were related to the single and multiplex autoantibodies). The selection process is shown in [Fig 1](#pone.0182117.g001){ref-type="fig"}.

![Flow diagram showing the inclusion and exclusion of studies.](pone.0182117.g001){#pone.0182117.g001}

Characteristics of the study populations with single and multiplex autoantibodies {#sec013}
---------------------------------------------------------------------------------

For the studies with single autoantibody, the 31 articles (with 38 tests) included participants from 8 countries ([Table 1](#pone.0182117.t001){ref-type="table"}). The most studied populations were Chinese \[[@pone.0182117.ref035],[@pone.0182117.ref045],[@pone.0182117.ref065],[@pone.0182117.ref075],[@pone.0182117.ref079],[@pone.0182117.ref085],[@pone.0182117.ref087]--[@pone.0182117.ref092],[@pone.0182117.ref094]\] and Japanese \[[@pone.0182117.ref068],[@pone.0182117.ref077],[@pone.0182117.ref082],[@pone.0182117.ref083],[@pone.0182117.ref089],[@pone.0182117.ref096]\], followed by American \[[@pone.0182117.ref038],[@pone.0182117.ref071]--[@pone.0182117.ref073]\], Italian \[[@pone.0182117.ref078],[@pone.0182117.ref080],[@pone.0182117.ref093]\], and German \[[@pone.0182117.ref076],[@pone.0182117.ref095]\].The earliest study was from 1985, and anti-CSLEX1 antibody was the first tumor-associated autoantibody to be reported in patients with LC. The sample size of the included trials ranged from 28 to 813 individuals.

10.1371/journal.pone.0182117.t001

###### Studies investigating the single autoantibody.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference No.   Antigen        Author/\           Location\   LC\                  Control\               Detection method      Cut-off\                AUC     Se (%)\           Se (%)\   Sp (%)\           Accuracy (%), AS/ES   QAREL
                                 Year                           patients (AS/ES),\   patients (BD/NH), No                         value                           of AS             of ES     (BD/NH)                                 
                                                                No                                                                                                                                                                    
  --------------- -------------- ------------------ ----------- -------------------- ---------------------- --------------------- ----------------------- ------- ----------------- --------- ----------------- --------------------- -------
  35              ChgA           Qi/2015            China       168/168              97                     SAM                   [NR]{.ul}               0.688   47.6              47.6      80                58.7/58.7             5

  38              HSP70          Zhong/2003         USA         49                   40                     ELISA                 [NR]{.ul}               0.731   74                NR        73                73.0                  5

  38              HSP90          Zhong/2003         USA         49                   40                     ELISA                 [NR]{.ul}               0.602   59                NR        58                76.4                  5

  45              TIM            Zhang/2009         China       61                   NH59                   ELISA                 0.221                   0.790   65.6              NR        84.7              75                    5

  45              PRDX6          Zhang/2009         China       84/35                71(12/59)              ELISA                 0.151                   NR      70.5              NR        62.7              66.7                  5

  65              NY-ESO-1       Yang/2015          China       57/43                47                     ELISA                 [NR]{.ul}               0.619   37.2              30.2      91.7              61.5/62.2             7

  65              NSE            Yang/2015          China       57/43                47                     ELISA                 [NR]{.ul}               0.773   48.3              NR        90.9              65.4                  7

  68              HP217          Okano/2016         Japan       10                   18(10/8)               ELISA                 0.13                    NR      70                NR        72.2(60/87)       71.4                  5

  68              CYFRA          Okano/2016         Japan       10                   18(10/8)               ELISA                 3.0                     NR      70                NR        100               89.3                  5

  71              CSLEX1         Hirota/ 1985       USA         201                  612(332/280)           [CBI]{.ul}            [1:16]{.ul}             NR      43.8              NR        99.2(99.1/99.3)   85.5                  6

  72              CP             Gordon/1990        USA         22/3                 74(20/54)              ELISA                 0.57ug/ml               NR      86                100       87.8(80/91)       87.5/88.3             11

  73              CP             Kozwich/\          USA         12/3                 244(106/139)           ELISA                 225ng CP/ml             NR      83                100       83(83/82)         82.8/83.4             11
                                 1994                                                                                                                                                                                                 

  74              F023C5         Biggi/1991         Italy       66                   8(BD)                  Immuno scintigraphy   NR                      NR      90                NR        45                85                    5

  75              3C~9~Ag        Bai/1994           China       102                  172(76/96)             ELISA                 43%                     NR      64.7              NR        93                82.5                  5

  75              WLA-Ag~1~      Bai/1994           China       98                   103(49/54)             ELISA                 38%                     NR      50                NR        95.1              73.1                  5

  76              NSE            Ebert/1998         Germany     50                   NH98                   EIA II                12.3 ng/ml              NR      78                NR        95                89.3                  

  77              p53            Segawa/1998        Japan       52/17                NH:63                  ELISA                 7.2                     NR      46.1              NR        95                73.0                  5

  78              p53            Cioffi/2001        Italy       109/21               130(80/50)             ELISA                 ≥2.3 times of control   NR      32.1              42.9      100               69/92.1               5

  79              p53 IgG        Zhang/2014         China       271                  226                    ELISA                 NR                      0.57    90.4              NR        19.7              58.2                  5

  80              TLP            Tarro/2002         Italy       ES20                 25                     ELISA                 NR                      NR      NR                88        89.9              89.0                  5

  81              Recoverin      Bazhin/ 2004       Rusia       143                  136(86/50)             WB                    NR                      NR      20                NR        98                56.6                  5

  82              α-enolase      He/2007            Japan       94/31                NH60                   ELISA                 Mean+2SD                NR      27.7              NR        98.3              55.2                  5

  83              Nectin-4       Takano/\           Japan       164/24               NH131                  ELISA                 1.0ng\                  NR      53.7              25        97.7              73.2                  5
                                 2009                                                                                             /ml                                                                                                 

  84              α-crystallin   Cherneva/\         England     51                   52                     ELISA                 0.317                   0.712   62                NR        72                67.0                  5
                                 2010                                                                                                                                                                                                 

  85              DKK1           Yao/2010           China       93/38                NH87                   ELISA                 1.38                    NR      62                65.8      84                64.0/78.4             5

  86              SOX2           Maddison/\         UK          212                  NH212                  ELISA                 Mean+3SD                NR      33                NR        97                65                    5
                                 2010                                                                                                                                                                                                 

  87              Survivin       Ma/2010            China       215/44               109(20/89)             ELISA                 Mean+2SD:0.657          NR      19.5              24.1      88.9              42.9                  5

  88              ABCC3          Liu/2012           China       275                  226                    ELISA                 1.53/1.58(IgG/IgA)      NR      18.1/18.0 (F/M)   NR        \>95              53.1                  6

  89              CAXII          Kobayashi/\        Japan       70                   30                     Dot blot analysis     NR                      0.794   82.9              NR        70.0              79                    5
                                 2012                                                                                                                                                                                                 

  90              IGFBP-2        Zhang/2013         China       190                  104(31/71)             ELISA                 1,264.306ng/ml          0.677   73.2              NR        60.6              \                     5
                                                                                                                                                                                                                68.7                  

  91              CD25 IgG       Ye/2013            China       260/166              NH226                  ELISA                 NR                      0.70    35                32        \>90              33.6/65.3             6

  92              MUC1           He/2013            China       48                   27(7/20)               ELISA                 1.98ug/L                NR      62.5              NR        100               76                    5

  93              LGALS3BP       Grassadonia/2013   Italy       13                   54                     ELISA                 0.99                    NR      46                NR        98                88.1                  5

  79              p16 IgG        Zhang/2014         China       271                  226                    ELISA                 NR                      0.57    19.7              NR        90.4              51.8                  5

  94              ANXA1          Wang/2014          China       272                  NH227                  ELISA                 NR                      0.64    23.7              NR        90.3              54.0                  5

  94              DDX53          Wang/2014          China       272                  227                    ELISA                 NR                      0.52    13.8              NR        90.3              48.6                  5

  95              TPTE           Kuemmel/\          Germany     307                  47                     ELISA                 0.0305\                 NR      52                NR        72                54.6                  5
                                 2015                                                                                             (ROC)                                                                                               

  96              CANX           Kobayashi/\        Japan       195/116              100                    RPPA                  2.49                    0.980   99                NR        96.9              98.3                  5
                                 2015                                                                                                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LC = lung cancer; AS/ES = all-stage/early-stage; BD/NH = benign diseases/normal healthy donors; BN = benign nodule; AUC = area under the curve; Se = sensitivity; Sp = specificity; QAREL = The Quality Appraisal for Reliability Studies; ELISA = enzyme-linked immunoassay; WB = Western blotting; CBI = cell-binding inhibition assay; EIA = enzyme immunoassay; RPPA = reverse-phase protein array; NR = not reported; SAM = significance analysis of microarray; F/M = female/male; ROC = receiver operating characteristic curve.

For the studies with multiplex autoantibodies, the baseline characteristics of 39 articles (with 49 tests) are presented in Tables [2](#pone.0182117.t002){ref-type="table"} and [3](#pone.0182117.t003){ref-type="table"}. These studies were published between 1988 and 2016. The sample size of the included trials ranged from 28 to 2,099 individuals. Among the 12 tests from 7 articles used for the meta- analysis, 8 tests were based on the same panel of 6 TAAbs and 4 tests analyzed the same panel of 7 TAAbs.

10.1371/journal.pone.0182117.t002

###### Study summary of multiple autoantibodies in the systematic review.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference\   Author/\               Location\     Combination of antigens                                                              LC patients (ES), No   Controls\      Detection method   Cut-off\          AUC/\     Se (%)\   Se (%)\   Sp (%)\     Accuracy\   QAREL
  No.          Year\                                                                                                                                            (BD/NH), No\                      value             ES        of AS     of ES\    /ES\        (%) /ES     
  ------------ ---------------------- ------------- ------------------------------------------------------------------------------------ ---------------------- -------------- ------------------ ----------------- --------- --------- --------- ----------- ----------- -------
  13           Yao/2012               China         NOLC1, HMMR, MALAT1 and SMOX                                                         40(19)                 NH36           ELISA              NR                0.767     47.5      63.2      97.3        71.1/85.5   8

  14           Zhong/2006             USA           L1919,L1896,G2004,G1954 and G1689                                                    ES23                   NH23           Diagnostic chip    NR                0.99      NR        91.3      91.3        91.3        6

  34           Farlow/2010            USA           IMPDH, phosphoglycerate\                                                             117(81)                79 BD          WB                 NR                0.964     94.8      NR        91.1        93.4        5
                                                    mutase, ubiquillin, Annexin I, Annexin II, and HSP70-9B                                                                                                                                                               

  35           Qi/2015                China\        ChgA peptides (Pep16 and Pep29)                                                      168(168)               97             SAM                NR                0.688     47.6      47.6      80.0        59.4        5

  36           Schepart/\             USA           5E8, 5C7, and 1F10                                                                   18(3)                  BD43           ELISA              0.2ug             NR        67.0      100       81.0        77.0/82.6   
               1988                                                                                                                                                                                                                                                       

  37           Bai/1994               China         WLA-Ag~1~ and 3C~9~Ag                                                                96(15)                 172(96/76)     ELISA              Mean ±2SD         NR        75.0      NR        93.8        87.1        5

  38           Zhong/2003             USA           HSP70 and HSP90                                                                      49(11)                 NH40           ELISA              NR                0.742     78.0      NR        65.0        71.9        5

  39           Koziol/2003            USA           c-myc, cyclin B1, IMP1, Koc, p53, p62, and survivin                                  56                     NH346          ELISA              Mean ±2SD         NR        80.0      NR\       90.0        88.6        5

  40           Bazhin/2003            Russia        P40-p42,p36,p30,p28,p26,p14                                                          60                     NH115          WB                 NR                NR        80.0      NR        91          87.7        5

  41           Pereira-Faca/ 2007     USA           14-3-3 θ, Annexin 1 and PGP 9.5                                                      ES18                   19             WB                 NR                0.838     NR        55.0      95.0        75.7        7

  42           Chen/2007              USA           22-Autoantibodies                                                                    75                     BD50           PPM                NR                0.92      85.3      NR        86.0        85.6        8

  43           Leidinger/\            Germany       62 phage-peptide clones                                                              39(18)                 69(29/40)      Bayes classifier   NR                0.945     83.4      NR        93.9        90.1/92.9   5
               2008                                                                                                                                                                                                                                                       

  43           Leidinger/\            Germany       80 phage-peptide clones                                                              ES18                   NH40           Bayes classifier   NR                0.998     NR        79.0      99.2        92.9        5
               2008                                                                                                                                                                                                                                                       

  44           Chapman/\              UK            p53, c-myc, HER2, NY-ESO-1, CAGE, MUC1 and GBU4-5                                    104(9)                 NH50           ELISA              Mean+2SD or 3SD   NR        76.0      88.9      92.0        81.2/90.9   5
               2008                                                                                                                                                                                                                                                       

  45           Zhang/2009             China         TIM and PRDX6                                                                        61(35)                 NH59           ELISA              NR                0.79      65.5      NR        84.7        75.0        5

  46           Han/2009               South Korea   AQP5,ARTN,CKB,TAF9,TGIF2 and MCM3                                                    17                     NH15           Micro-\            NR                NR        88.0      NR        80.0        84.0        10
                                                                                                                                                                               array                                                                                      

  47           Khattar/2010           USA           Phage 908, 3148, 1011,3052 and 1000                                                  32(11)                 NH30           Peptide Library    NR                0.982     90.6      NR        73.3        82.0        7

  48           Wu/2010                China         Six-Phage peptide clones 72, 91, 96, 252, 286 and 290                                90(21)                 NH90           Bayes classifier   NR                0.956/\   92.2      92.2      92.2/85.7   92.2/86.9   6
                                                                                                                                                                                                                    0.888                                                 

  49           Rom/2010               USA           c-myc, Cyclin A, Cyclin B1, Cyclin D1, CDK2, and survivin                            22                     NH36           ELISA              Mean+3SD          0.907     81.0      NR        97.0        91.4        5

  50           Murray/2010            UK            GBU4-5(G1), CAGE(P1), p53(P1) and NY-ESO-1(P1),                                      145                    146            ELISA              Mean+3SD          NR        35.0      NR        90.0        62.5        8

  51           Leidinger/\            Germany\      1827 proteins                                                                        47(22)                 106(26/80)     SVMs               NR                0.5       97.9      75.9      97/97.6     97.6/92.9   6
               2010                                                                                                                                                                                                                                                       

  53           Guergova- Kuras/2011   France        C9,LRG,Hpt,ACT and CFH                                                               301(129)               347(112/235)   ELISA              NR                0.88      77.0      NR        87.0        82.4        5

  53           Guergova-Kuras/\       France        C9,LRG1,Hpt,ACT and CYFRA                                                            301(129)               347(112/235)   ELISA              NR                0.93      84.0      83.0      95/95       90.0/91.8   5
               2011                                                                                                                                                                                                                                                       

  54           Chapman/\              UK            p53, NY-ESO-1, HuD, CAGE, GBU4-5, Annexin 1 and SOX2                                 243(14)                247            ELISA              Mean+2SD          0.76      42        50        99          70.8/96.6   6
               2011                                                                                                                                                                                                                                                       

  56           Macdonald/\            UK            alpha enolase BirA, p53, C-BirA, cytokeratin 8 BirA, cytokeratin 20 BirA and Lmyc2   265                    265            ELISA              NR                NR        49.0      NR        93.0        70.9        5
               2012                                                                                                                                                                                                                                                       

  58           Izbicka/2012           USA           EGF, sCD40 ligand, IL-8, sFas, MMP-9 and PAI-1                                       166                    NH130          SVM                NR                NR        99        NR        95          97.3        5

  59           Shan/2013              China         NY-ESO-1, XAGE-1, ADAM29 and MAGEC1                                                  120(69)                NH68           Microarray         Mean+2SD          NR        33.0      27.5      96          55.9/61.3   5

  60           Pedchenko/\            USA           6 selected scFvs (B6,3E,G1,P6 and J1)                                                ES22                   21             MSD assay          NR                0.72      NR        61.0      71.0        65.8        5
               2013                                                                                                                                                                                                                                                       

  62           Wang/2014              China         Imp1, p62, Koc, p53, C-myc, Cyclin B1, Survivin, and p16.                            98                     58             ELISA              Mean+2SD          NR        64.3      NR        86.2        72.4        5

  63           Trudgen/\              USA           APEX1,NOLC1,SF3A3,PXN,R-580E16 and MT-RNR2                                           19(5)                  237            ELISA              NR                640FU     58        80.0      43          44.1/43.8   10
               2014                                                                                                                                                                                                                                                       

  65           Yang/2015              China         NY-ESO-1+NSE                                                                         57(43)                 47             ELISA              NR                0.83      69.1      NR        91.8        77.0        7

  66           Doseeva/\              USA           NY-ESO-1, CEA, CA-125 and CYFRA 21--1                                                190(160)               115            xMAP               6.4               0.83      72        71.2      83.0        76.0/76.0   7
               2015                                                                                                                                                                                                                                                       

  67           Wang/2016              USA           TTC14,BRAF, MORC2, ACTL2B and CTAG1B                                                 137(110)               NH127          ELISA              \>98%\            NR        30.0      NR        89.0        54.5        5
                                                                                                                                                                                                  control                                                                 

  67           Wang/2016              USA           KRT8,TTC14,KLF8,BRAF and TLK1                                                        137                    BN170          ELISA              \>98%\            NR        33.0      NR        88.0        63.5        5
                                                                                                                                                                                                  control                                                                 

  68           Okano/2016             Japan         HP217 and CYFRA                                                                      10                     18(10/8)       ELISA              0.13/3.0          NR        100       NR        72.2        82.1        5

  70           Dai/2016               China,\       14-3-3,c-Myc, MDM2, NPM1, p16, p53 and cyclin B1                                     90(60)                 NH89           ELISA              NR                0.863     68.9      NR        79.5        74.3        5
                                      USA                                                                                                                                                                                                                                 

  70           Dai/2016               China,\       14-3-3,c-Myc, MDM2, NPM1, p16, p53 and cyclin B1                                     25(21)                 NH56           ELISA              NR                0.885     76.0      NR        73.2        75.2        5
                                      USA                                                                                                                                                                                                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LC = lung cancer; AS/ES = all-stage/early-stage; BD/NH = benign diseases/normal healthy donors; BN = benign nodule; AUC = area under the curve; Se = sensitivity; Sp = specificity; QAREL = The Quality Appraisal for Reliability Studies; ELISA = enzyme-linked immunoassay; WB = Western blotting; PPM = Phage-peptide microarrays; FU = fluorescent unit; SVMs = Support Vector Machines; MSD = Mesa Scale Discovery; xMAP = flexible Multi-Analyte Profiling; NR = not reported; SAM = significance analysis of microarray.

10.1371/journal.pone.0182117.t003

###### Study summary of a panel of autoantibodies in the meta-analysis.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference\   Author/\        Location\   Combination\   LC\                 Controls\   Detection method   Cut-off\   AUC    Se(%) of AL   Se(%) of ES   Sp (%)\   Accuracy (%),AL/ES   QAREL
  No.          Year                        of auto-\      patients (ES), No   , No                           value                                                                        
                                           antibodies                                                                                                                                     
  ------------ --------------- ----------- -------------- ------------------- ----------- ------------------ ---------- ------ ------------- ------------- --------- -------------------- -------
  50           Murray/2010     UK,USA      6 TAAbs        241                 240         ELISA              Mean+3SD   NR     34            NR            91        62.5                 8

  50           Murray/2010     UK,USA      6 TAAbs        269                 269         ELISA              Mean+3SD   NR     37            NR            90        63.6                 8

  52           Lam/2011        Canda,\     6 TAAbs        574(296)            802         ELISA              Mean+3SD   NR     39            29.7          87        67.0/71.6            10
                               UK,USA                                                                                                                                                     

  55           Boyle/2011      France      6 TAAbs        145(123)            145         ELISA              Mean+3SD   0.71   36            NR            91        63.4                 10

  55           Boyle/2011      France      6 TAAbs        241(1)              240         ELISA              Mean+3SD   0.63   39            NR            89        64.0                 5

  55           Boyle/2011      France      6 TAAbs        269(139)            269         ELISA              Mean+3SD   0.64   37            NR            90        63.6                 5

  57           Chapman/ 2012   UK          6 TAAbs        235                 266         ELISA              Mean+2SD   NR     39            NR            89        65.7                 10

  64           Jett /2014      UK          6 TAAbs        26                  726         ELISA              Mean+2SD   NR     46            NR            83        81.8                 10

               Overall                                    2,000(559)          2,957                                                                                                       

  57           Chapman/ 2012   UK          7 TAAbs        235(159)            266         ELISA              Mean+2SD   NR     41            40            91        67.5/72.0            10

  61           Healey/2013     UK          7 TAAbs        607(393)            1,492       ELISA              Mean+2SD   NR     66            NR            91        83.8                 9

  64           Jett /2014      UK          7 TAAbs        35                  812         ELISA              Mean+2SD   NR     37            NR            91        88.8                 10

  69           Massion /2016   UK          7 TAAbs        37                  129         ELISA              Mean+2SD   NR     38            NR            84        73.5                 9

               Overall                                    914(552)            2,699                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LC = lung cancer; AS = all-stage, ES = early-stage; AUC = area under the curve; Se = sensitivity; Sp = specificity; NR = not reported; QAREL = The Quality Appraisal for Reliability Studies; ELISA = enzyme-linked immunoassay; TAAbs = tumor-associated autoantibodies; 6 TAAbs = p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2; 7 TAAbs = p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD and MAGE A4.

Tumor-associated autoantibody detection methods {#sec014}
-----------------------------------------------

Whether the studies with single autoantibody or with combinations of multiple autoantibodies, the most commonly used detection method was enzyme-linked immunoassay (ELISA), with 31 out of 38 tests for single autoantibody and 33 out of 49 tests for multiple autoantibodies. Other detection methods included Western blot (WB), phage-peptide microarray, Bayes classifier and significance analysis of microarray (SAM) et al. For the commercial panel of mixed TAAbs, the technology used to detect serum TAAbs was ELISA.

To differentiate positive and negative samples, studies most commonly used the mean absorbance or level of the TAAbs in the control group plus two or three standard deviations (SDs), or the cut-off value was determined according to the receiver operating characteristic (ROC) curve.

Quality assessment of individual studies {#sec015}
----------------------------------------

For the systematic review of studies of single or multiple autoantibodies, the quality of the study design and reporting diagnostic reliability of most studies was poor since only 2 out of 38 tests with single autoantibodies or 5 out of 37 tests with combinations of multiple autoantibodies had high QAREL scores (≥8) (Tables [1](#pone.0182117.t001){ref-type="table"} and [2](#pone.0182117.t002){ref-type="table"}). The items about examiner blinding resulted in the greatest number of "no" scores. For the meta-analysis of studies of the same panels of mixed autoantibodies, however, the methodological quality of most studies was generally good because 10 of 12 tests had high QAREL scores ([Table 3](#pone.0182117.t003){ref-type="table"}).

Diagnostic value of single tumor-associated autoantibody for any stage lung cancer {#sec016}
----------------------------------------------------------------------------------

In [Table 1](#pone.0182117.t001){ref-type="table"}, we have listed the single TAAb in the diagnosis of lung cancer. Overall, considering the 38 tests results for 34 specific TAAbs originating from 31 articles, the sensitivities ranged from 13.8% to 99% (mean:55.2, median: 53.7%) and the specificities ranged from 19.7% to 100% (mean:84.4, median: 90.3%). However, the diagnostic sensitivity in 17 (44.7%) individual autoantibodies was lower than 50%. Three articles reported the autoantibody against p53 \[[@pone.0182117.ref078]--[@pone.0182117.ref079]\], with the sensitivities ranging from 32.1% to 90.4% and the specificities ranging from 19.7% to 100%; two articles reported the autoantibody against neuron-specifi c enolase (NSE), the sensitivities were 48.3% and 78%, while their specificities were 90.9% and 95%, respectively \[[@pone.0182117.ref065],[@pone.0182117.ref076]\].

Diagnostic value of multiple autoantibodies for patients at all stages of lung cancer {#sec017}
-------------------------------------------------------------------------------------

The diagnostic values of mixed TAAbs for all lung cancer stages are listed in [Table 2](#pone.0182117.t002){ref-type="table"}. There were 33 test results for mixed TAAbs originating from 30 articles. The sensitivities ranged from 30% to 100% (mean: 70.3%, median: 77.0%), the specificities ranged from 43% to 97.3% (mean: 86.3%, median: 90.5%), and the accuracy ranged from 44.1% to 97.6% (mean: 77.7%, median: 81.2%). In three articles, both of the sensitivity and specificity of combinations of multiplex autoantibodies were greater than 90%, which included group 1 (six-phage peptide clones 72, 91, 96, 252, 286 and 290) \[[@pone.0182117.ref048]\], group 2 (1827 proteins) \[[@pone.0182117.ref051]\] and group 3 (EGF, sCD40 ligand, IL-8, sFas, MMP-9 and PAI-1) \[[@pone.0182117.ref058]\]. Sixteen out of 33 tests had the diagnostic accuracy \>80%.

Meta-analysis of the same panel of autoantibodies for any stage lung cancer {#sec018}
---------------------------------------------------------------------------

Eight tests with the same panel of 6 TAAbs (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2) were selected for meta-analysis. These studies were published between 2010 and 2014. The sample size of the included studies ranged from 281 to 1,376 individuals (total 4,957). The pooled estimate of sensitivity and specificity of this analysis was 38% (range 34--46%, 95% CI 0.35--0.40) and 89% (range 83%-91%, 95% CI 0.86 to 0.91), respectively ([Fig 2](#pone.0182117.g002){ref-type="fig"}). The diagnostic accuracy ranged from 62.5% to 81.8% (mean: 65.9%) ([Table 3](#pone.0182117.t003){ref-type="table"}), while the area under curve (AUC) was 0.52 (0.48--0.57) ([Fig 3](#pone.0182117.g003){ref-type="fig"}-left), indicating a relative low level of overall diagnostic accuracy with the panel of 6 TAAbs. The pooled specificity of the heterogeneity test indicated that there was a moderate heterogeneity between studies (Q = 136.08, I^2^ = 94.86%, P = 0.00). Subsequently, we performed sensitivity analyses to explore potential sources of heterogeneity. The exclusion of the trial conducted by Jett and colleagues \[[@pone.0182117.ref064]\] resolved the heterogeneity, but did not change the pooled results (sensitivity 37%, 95% CI 0.35--0.40; specificity 89%, 95% CI 0.88--0.91; *P* for heterogeneity = 0.50, I^2^ = 0%; AUC = 0.55).

![Forest plot of estimates of the panel of 6 TAAbs for sensitivity (left) and specificity (right) for diagnosing lung cancer.](pone.0182117.g002){#pone.0182117.g002}

![Summary receiver operating characteristic curves (SROC) for the panel of 6 TAAbs (left) and 7 TAAbs (right) for diagnosing lung cancer.](pone.0182117.g003){#pone.0182117.g003}

Four studies that included 3,613 patients (cancer patients/controls = 914/2,699) explored the diagnostic value of the panel of 7 TAAbs (p53, CAGE, NY-ESO-1, GBU4-5, SOX2, MAGE A4 and Hu-D). The pooled estimates of this test were: sensitivity 47% (range 37--66%, 95% CI 0.34--0.60), specificity 90% (range 84%-91%, 95% CI 0.89--0.92), diagnostic accuracy 78.4% (range 67.5--88.8%), respectively, with P = 0.000 indicating a significant heterogeneity between studies. In addition, the overall AUC was 0.90 (0.87--0.93), indicating a moderate diagnostic accuracy with the panel of 7 TAAbs ([Fig 3](#pone.0182117.g003){ref-type="fig"}-right, [Fig 4](#pone.0182117.g004){ref-type="fig"}).

![Forest plot of estimates of the panel of 7 TAAbs for sensitivity (left) and specificity (right) for diagnosing lung cancer.](pone.0182117.g004){#pone.0182117.g004}

Diagnostic value of single or multiple autoantibodies for early stage lung cancer {#sec019}
---------------------------------------------------------------------------------

For single TAAb in the diagnosis of early -stage lung cancer, there were 10 specific TAAbs (including CP, p53, TLP, Nectin-4, DKK1 and Survivin) originating from 10 articles for the analysis, with the sensitivities ranged from 24.1% to 100%, the specificities ranged from 24.1% to 97.7% and the accuracy ranging from 58.7 to 92.1% (mean 73.4, median 75.8) ([Table 1](#pone.0182117.t001){ref-type="table"}). Both of articles reported the sensitivity of CP was 100%, but the sample size was small (both with only 3 early stage LC patients) \[[@pone.0182117.ref072],[@pone.0182117.ref073]\].

For the panel of mixed TAAbs in detecting early-stage lung cancer patients, 15 studies involving 2,239 patients (700 patients in the early stage lung cancer group and 1,539 in the control group) were included in our analysis. The results showed that the sensitivities ranged from 27.5 to 100% (mean: 71.1%, median: 71.2%), the specificities ranged from 43.8% to 99.2% (mean: 87.1%, median: 91.3%) and the accuracy ranged from 43.8% to 96.6% (mean: 79.6%, median: 82.6%) for the diagnosis of early-stage lung cancer([Table 2](#pone.0182117.t002){ref-type="table"}). Our data demonstrated that different combinations of multiple autoantibodies have different diagnostic values for detecting early-stage lung cancer.

For the commercial panel of mixed TAAbs for the diagnosis early-stage lung cancer, the single study reported the sensitivity, specificity and accuracy of 29.7%, 87.0% and 71.6% in the panel of 6 TAAbs \[[@pone.0182117.ref052]\] and 40%, 91% and 72.0% in the panel of 7 TAAbs \[[@pone.0182117.ref057]\], respectively. It appears that the diagnostic value of the panel of 7 TAAbs is higher than the panel of 6 TAAbs.

Evaluation of publication bias {#sec020}
------------------------------

Publication bias was assessed, but the analysis of only 8 studies with 6 TAAbs or 4 publications with 7 TAAbs in the meta-analysis decreased the power of the publication bias analysis and limited the interpretability of the findings.

Discussion {#sec021}
==========

Different lung cancer patients are unlikely to respond to the same immunogenic antigens because of the histological heterogeneity of cancer. Even cancers of the same type are composed of different biological subtypes. In this study, for the first time, we performed a systematic review and meta-analysis to evaluate the diagnostic value of serum single or multiplex TAAbs for individuals with potential LC. Our results indicated that the single or different combination of multiple autoantibodies may have different diagnostic values for identifying patients at all stages or early-stage of lung cancer from healthy controls or benign diseases. Although the individual TAAbs showed low diagnostic sensitivity, the combination of multiplex autoantibodies offered relatively high sensitivity, and some panels of multiplex TAAbs could have promising sensitivity and specificity (both \> 90%). In the present meta-analysis of a panel of TAAbs, our data demonstrated that a moderate diagnostic accuracy was achieved with the panel of 6 TAAbs or 7 TAAbs in the diagnosis all-stage lung cancer, given their AUCs of 0.52 and 0.90, respectively, indicating that the diagnostic value of the panel of 7 TAAbs was higher than the panel of 6 TAAbs in the diagnosis of lung cancer, especially in early-stage patients.

Two recent reviews \[[@pone.0182117.ref011],[@pone.0182117.ref016]\] summarized some recent advances in blood-based lung cancer biomarkers that have the potential to be clinically useful in the near future, the authors found that only the miRNA signatures (the miR-Test for serum and the miRNA signature classifier test for plasma) and autoantibodies to TAAs are being assessed as noninvasive tests to detect lung cancer at the early stage. However, both of the reviews did not perform a meta-analysis of the same panel of autoantibodies. Our comprehensive review indicated that different single or combinations of multiple autoantibodies have different diagnostic abilities for detecting patients at all stages of LC, almost half of the diagnostic sensitivities in individual autoantibodies was lower than 50%. However, the combination of multiplex autoantibodies offered a relatively higher sensitivity than that of single autoantibody, with the sensitivities ranging from 30% to 100% (mean: 70.3%, median: 77.0%), the specificities ranging from 43% to 97.3% (mean: 86.3%, median: 90.5%), and the accuracy ranging from 44.1% to 97.6% (mean: 77.7%, median: 81.2%). Many combinations of multiplex autoantibodies were found to have promising value for detecting LC. *Wu* et al.\[[@pone.0182117.ref048]\] discovered autoantibody signatures to six--phage peptide clones (72, 91, 96, 252, 286 and 290) by two-step immunoscreenings and validated them in an independent set of 90 non-small cell lung cancer (NSCLC) patients and 90 matched healthy controls, 30 NSCLC patients undergoing chemotherapy, and 12 chronic obstructive pulmonary disease (COPD) patients. The six-phage peptide detector was able to discriminate between NSCLC patients and healthy controls with a sensitivity and specificity of \>92%, and had similar value for detecting NSCLC at an early stage. The seroreactivity of the six-phage peptides was also significantly higher in the NSCLC patients than in those with chemotherapy and the COPD patients. Leidinger et al.\[[@pone.0182117.ref051]\] reported that an autoantibody profile consisting of 1827 integer intensity values ranging from 0 to 255 can discriminate LC patients from controls without any lung disease with a specificity of 97.0%, a sensitivity of 97.9%, and an accuracy of 97.6%. The classification of stage IA/IB tumors and controls yielded a specificity of 97.6%, a sensitivity of 75.9%, and an accuracy of 92.9%. Izbicka et al. \[[@pone.0182117.ref058]\] studied a set of autoantibodies (EGF, sCD40 ligand, IL-8, sFas, MMP-9 and PAI-1) as potential biomarkers. Mass spectrometry was used for biomarker discovery. A support vector machine (SVM) was used for data analysis. They found that the panel of autoantibodies was able to discriminate NSCLC patients from healthy controls with a sensitivity and specificity of 99% and 95%, respectively. However, the quality of study design and reporting diagnostic reliability were generally poor since the three publications had low QAREL scores (\<8), and none of them were performed with the most commonly used detection methods, i.e. ELISA. Therefore, single autoantibody is seldom able to detect all LC with a high enough specificity and sensitivity, whereas the detection of combinations of multiple markers could significantly improve the diagnostic performance \[[@pone.0182117.ref013],[@pone.0182117.ref068]\].

In the present meta-analysis, our results showed that the pooled sensitivities of a panel of 6 TAAbs and 7 TAAbs were 38% and 47%, respectively, and their specificities were 89% and 90%, respectively. The panel of 7 TAAbs yielded an AUC on a combined SROC curve of 0.90, indicating that its level of accuracy was higher than that of the panel of 6 TAAbs with an AUC of 0.52. Moreover, exclusion of a single study among the 6 TAAbs and sensitivity analyses did not materially alter the pooled results, which adds robustness to our main finding. However, both sensitivities were not very good, which indicates that a negative test result does not rule out lung cancer in the screening setting. The antigens of the panel of 6 TAAbs are p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2. In brief, autoantibodies to p53 tumor suppressor gene, which is often mutated in a variety of malignancies (including in lung, colorectal and breast cancer), can be detected before the diagnosis of cancer in smokers with chronic obstructive pulmonary disease \[[@pone.0182117.ref097]\]. Besides expressed in prostate, breast, colorectal cancer and melanoma patients, the presence of antibodies to NY-ESO-1 were significantly elevated in NSCLC patients with an active smoking history and was more expressed in early NSCLC stages than in late stage \[[@pone.0182117.ref066],[@pone.0182117.ref098]\]. CAGE has been reported in a variety of cancers, but not in normal tissues \[[@pone.0182117.ref099]\]. Autoantibodies to SOX2 are considered to be mainly detected in small cell lung cancer (SCLC) \[[@pone.0182117.ref100]\] The remaining antigens GBU4-5 and Annexin I are also expressed in lung cancer \[[@pone.0182117.ref054],[@pone.0182117.ref055]\]. The panel of 7 TAAbs comprised two antigens (MAGE A4 and HuD) in addition to the other well-described cancer-associated antigens (p53, NY-ESO-1,CAGE, GBU4-5, and SOX2). It is possible that adding melanoma-associated antigen A4 (MAGE-A4) and HuD to the panel, which are known to have particular associations with lung cancer, may improve the sensitivity and optimize the test accuracy. MAGE A4 has been demonstrated to be expressed in melanomas and NSCLC patients (male gender, with a smoking history), especially in squamous cell carcinoma patients \[[@pone.0182117.ref098],[@pone.0182117.ref100],[@pone.0182117.ref101]\]. Approximately half of squamous cell carcinoma (SCC) expressed MAGE-A4 \[[@pone.0182117.ref102]\], and MAGE A4 has been proposed as a potential therapeutic target for immunotherapy \[[@pone.0182117.ref103]\]. HuD is a neuronal RNA-binding protein, and the HuD-antigen is expressed in 100% of SCLC tumor cells and over 50% of neuroblastoma cells \[[@pone.0182117.ref104]\]. In fact, anti-HuD autoantibody was detected only in SCLC cases with or without paraneoplastic encephalomyelitis/sensory neuronopathy (PEM/SN), but not in the sera of large cell neuroendocrine carcinoma (LCNEC) patients \[[@pone.0182117.ref105]\]. It means that autoantibodies to HuD could serve as a good marker for SCLC. Based on the QAREL score to assess the quality of diagnostic reliability, 10 of 12 publications in the meta-analysis had higher QAREL scores (≥8), suggesting that the overall methodological quality of most studies was good.

Searching for potential biomarkers of early-stage lung cancer in a high-risk population is urgently required, as this could have a markedly beneficial and clinically significant impact on patient survival \[[@pone.0182117.ref068]\]. Autoantibodies to TAAs has been shown to be present in patient blood for as much as 5 years before the presentation of clinical symptoms \[[@pone.0182117.ref014],[@pone.0182117.ref044],[@pone.0182117.ref106]\]. A wide variety of single or combinations of multiple autoantibodies have been reported, some of which may contribute to the diagnosis of early-stage lung cancer, while others are likely to have less diagnostic value. Our data demonstrated that different single or combinations of multiple autoantibodies have different diagnostic values for detecting early-stage lung cancer. For single TAAb in the diagnosis of early -stage lung cancer, the sensitivities ranged from 24.1% to 100%, the specificities ranged from 24.1% to 97.7% and the accuracy ranging from 58.7 to 92.1% (mean 73.4, median 75.8). Two articles reported the sensitivity of cancer procoagulant (CP) was 100% \[[@pone.0182117.ref072],[@pone.0182117.ref073]\], which is expressed by a variety of malignant cells and may has potential role in the detection of early stage cancer, but the small sample size (both with only 3 early stage LC patients) in the two studies may cause an overestimation of the true effect.

For the combinations of mutiplex TAAbs in detecting early-stage lung cancer patients, the sensitivities ranged from 27.5% to 100%, and specificities ranged from 43.8% to 99.2%. Schepart *et al*.\[[@pone.0182117.ref036]\] reported a panel of three monoclonal antibodies (MAbs) (SE8, SC7, and 1F10) detected in three patients with Stage I or II squamous cell carcinoma. Both Leidinger et al. \[[@pone.0182117.ref043]\] and Wu et al. \[[@pone.0182117.ref048]\] found that 80 or 6 phage-peptide clones have a high accuracy for the diagnosis of early-stage lung cancer, with a sensitivity of 79.0% or 92.2%, respectively. In a study conducted by Chapman and colleagues \[[@pone.0182117.ref044]\], seven cancer-associated proteins (p53, c-myc, HER2, NY-ESO-1, CAGE, MUC1, and GBU4-5) were selected as markers of lung cancer with a sensitivity of 88.9% and specificity of 92% in patients with stage I-II NSCLC, but the sample size with only 9 early-stage LC patients makes the evidence limited. In another study conducted by the same authors \[[@pone.0182117.ref057]\], a different panel of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1, SOX2 and HuD) had a sensitivity of 50% and specificity of 99% in detecting SCLC patients. Some studies investigated other combinations of autoantibodies, for example, the panel of five monoclonal antibodies (C9, LRG, Hpt, ACT and CFH) \[[@pone.0182117.ref053]\], the panel of 4TAAbs (NOLC1, HMMR, MALAT1 and SMOX) \[[@pone.0182117.ref013]\] or the combination of NY-ESO-1 plus 3 tumor antigens (CEA, CA-125, and CYFRA 21--1) \[[@pone.0182117.ref066]\], to distinguish early-stage cancers from controls, and found that these different combinations of multiple autoantibodies have a high diagnostic accuracy for detecting early-stage lung cancer. However, some combinations of autoantibodies have a low sensitivity, for example, the panel of 14-3-3 θ, Annexin 1 and PGP 9.5, with a sensitivity of 55.0%; the panel of NY-ESO-1, XAGE-1, ADAM29 and MAGEC1 with a sensitivity of 27.5%, and the ChgA peptides (Pep16 and Pep29) with a sensitivity of 47.6%. Using a commercial biomarker assay of EarlyCDT-Lung test, Lam et al. \[[@pone.0182117.ref052]\] included 296 stageⅠ-Ⅱ NSCLC or limited SCLC patients, and found that the sensitivity, specificity and accuracy in the above-mentioned panel of 6 TAAbs were 29.7%, 87.0% and 71.6%, respectively. While Chapman al.\[[@pone.0182117.ref057]\] investigated the diagnostic value of 7 TAAbs in 159 early-stage patients, with a sensitivity, specificity and accuracy of 40%, 91% and 72.0%, respectively. Both of them can be detected in the early-stage lung cancer patients, with the AUCs 0.52 and 0.90, respectively, the diagnostic value of the panel of 7 TAAbs appears to be higher than the panel of 6 TAAbs.

There are some limitations to our study. First, we only searched two databases; therefore, we could not guarantee that all relevant studies were included. Second, the inclusion of studies published in English or Chinese may have resulted in publication bias. Third, the compositions of single or multiplex autoantibody combinations were very heterogeneous from study to study and various detection methods and cut-off points were used to distinguish LC patients from controls, which may have a potential impact on our results. It should be mentioned that, although blood-based autoantibodies have a great potential for use in the near future, these tests cannot yet be used as stand-alone tests, as they must be integrated with LDCT scan imaging in the screening procedure.

In summary, our study demonstrated that combinations of serum single or multiplex TAAbs may be useful biomarkers for discriminating LC patients at all stages or an early-stage from healthy controls or benign diseases, but the combination of multiplex autoantibodies shows a higher detection capacity; the diagnostic value of the panel of 7 TAAbs is higher than the panel of 6 TAAbs, which may be used as potential biomarkers for the early detection of LC. For physicians, a serum test integrated with LDCT scan imaging could be used as a screening tool to identify patients with suspected asymptomatic LC. Further study is needed to improve the sensitivity and specificity of the panel of autoantibodies according to different TAAs combinations.
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LC

:   Lung cancer

TAAbs

:   tumor-associated autoantibodies

LDCT

:   low-dose spiral computed tomography

TAA

:   tumor-associated antigen

AUC

:   under the curve

QAREL

:   quality appraisal tool for studies of diagnostic reliability

SROC

:   summary receiver operating characteristic curve

ELISA

:   enzyme-linked immunoassay

WB

:   Western blot

SCLC

:   small cell lung cancer

NSCLC

:   non-small cell lung cancer

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
